Has Sassan Hassassian, MD received payments from drug or device companies?

Yes. Drug and device makers reported $23,663 in general payments to Sassan Hassassian, MD across 457 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sassan Hassassian, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sassan Hassassian, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sassan Hassassian, MD

Interventional Pain Medicine · Manassas, VANPI 1093719536

Payments from drug & device makers

$23,663in general payments, 2019–2025

Across 457 payments — averaging $51.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Abbott$16K
Medtronic$2K
Collegium Pharmaceutical, Inc.$1K
Scilex Pharmaceuticals Inc.$547
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$483
Vertos Medical, Inc.$323
plus $3K from 36 others

$1,025in research payments, 2019–2025

Across 1 payment — averaging $1025.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Medtronic$1K

What the payments were for

Consulting fees$6,34027%
Speaking & faculty fees$3,90316%
Travel & lodging$1,5427%
Food & beverage$11,87850%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Abbott	144	$16,238
Medtronic(2 entities)	28	$1,583
Collegium Pharmaceutical, Inc.	79	$1,101
Scilex Pharmaceuticals Inc.	27	$547
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	36	$483
Vertos Medical, Inc.	2	$323
Boston Scientific	11	$317
AbbVie(2 entities)	13	$304
Si-bone, Inc.	5	$251
Amgen(2 entities)	9	$246
Biodelivery Sciences International, Inc.	16	$214
Azurity Pharmaceuticals, Inc.	8	$168
Almatica Pharma LLC	8	$152
GRT US Holding, Inc.	2	$152
Biotronik NRO, Inc.	1	$143
Assertio Therapeutics, Inc.	7	$134
Merz North America, Inc.	1	$124
Lundbeck LLC	4	$107
Pfizer	6	$105
Johnson & Johnson	5	$104
Arbor Pharmaceuticals, Inc.	5	$87
Nevro Corp.	4	$79
Merz Pharmaceuticals, LLC	3	$69
Lilly USA, LLC	4	$65
Teva Pharmaceuticals USA, Inc.	4	$63
Ferring Pharmaceuticals Inc.	2	$53
Fidia Pharma USA Inc.	2	$49
Averitas Pharma Inc.	2	$49
Pacira Therapeutics, Inc.	2	$41
Vertex	2	$38
Painteq LLC	1	$37
Cumberland Pharmaceuticals, Inc.	1	$36
Redhill Biopharma Inc.	2	$32
Kowa Pharmaceuticals America, Inc.	2	$28
Shionogi Inc	2	$25
Bioventus LLC	1	$25
Vertical Pharmaceuticals, LLC	1	$19
Pacira Pharmaceuticals Incorporated	1	$17
Stimwave Technologies Incorporated	1	$16
Forte Bio-pharma LLC	1	$14
Tersera Therapeutics LLC	1	$11
Electronic Waveform Lab, Inc.	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,663 in reported general payments places this provider in the 90th percentile of 52 interventional pain medicine providers in Virginia.

See all interventional pain medicine providers in Virginia →

Medicare billing

Part B allowed, 2024

$339,666

Medicare patients

299

Services billed

6,914

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Buprenorphine	22	$4,414
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	81	$1,376
Gabapentin	190	$978
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	70	$766
Tramadol Hcl-AcetaminophenTramadol Hcl/Acetaminophen	68	$596
Celecoxib	27	$453
Methocarbamol	73	$441
Morphine Sulfate ErMorphine Sulfate	14	$375
Pregabalin	38	$320
Tramadol Hcl	60	$238
Duloxetine Hcl	19	$190
Oxycodone Hcl	13	$78
Tizanidine Hcl	17	$35

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Manassas

Usman ZafarManassas$4K
Deeni BassamManassas$4K
Talal GhazalArlington$248K
Ketan PatelHaymarket$133K
Che TorryNewport News$48K
Benjamin SeemanRichmond$28K
Niteesh BhararaReston$25K
Raj SurejaNewport News$23K
Alok GopalWinchester$16K
Akhtar PurvezCharlottesville$15K

See the full list for Virginia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →